IFNG and cancer: Although these innovative cell-mediated immunotherapies have not been tested on patients yet, the encouraging results on the recruitment of myeloid cells at the TME, the low but persistent release of IL12 and IFNγ, and the trafficking and activation of anti-cancer cells in the TME suggest improved tolerability, reduced toxicity, better efficacy of the treatment, and reduced off-target distribution of the therapy.